-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, September 2 News China Biopharmaceuticals (HK.
01177) held the 2021 interim results meeting in Beijing on August 31
.
In addition to the various data, the outside concern about Zhongsheng Pharmaceutical also includes the company's countermeasures when the regulation of the pharmaceutical industry enters the deep water zone
.
Mao Li, the Chief Medical Officer (CMO) of Zhongsheng Pharmaceutical, who made his debut at the performance meeting, announced on the same day that he would officially launch the innovation transformation, accelerate the global strategic innovation network layout, and start the X-LAB project
.
01177) held the 2021 interim results meeting in Beijing on August 31
.
In addition to the various data, the outside concern about Zhongsheng Pharmaceutical also includes the company's countermeasures when the regulation of the pharmaceutical industry enters the deep water zone
.
Mao Li, the Chief Medical Officer (CMO) of Zhongsheng Pharmaceutical, who made his debut at the performance meeting, announced on the same day that he would officially launch the innovation transformation, accelerate the global strategic innovation network layout, and start the X-LAB project
.
The industry generally believes that under the new market situation, China's leading pharmaceutical companies will enter an international competitive landscape
.
Internationalization is also a strategic direction that Zhongsheng Pharmaceutical has adhered to for many years
.
"Zhongsheng Pharmaceutical will make every effort to consolidate high-quality development and launch the innovative transformation strategy X-LAB
.
" Mao Li said at the performance meeting that X-LAB's positioning is to strengthen the headquarters’ innovative R&D capabilities, accelerate international expansion, and empower The subsidiary’s business pipeline has formed a synergy with the subsidiary’s strong CMC, production, market and hospital network advantages to create version 2.
0 of China Biopharmaceuticals
.
.
Internationalization is also a strategic direction that Zhongsheng Pharmaceutical has adhered to for many years
.
"Zhongsheng Pharmaceutical will make every effort to consolidate high-quality development and launch the innovative transformation strategy X-LAB
.
" Mao Li said at the performance meeting that X-LAB's positioning is to strengthen the headquarters’ innovative R&D capabilities, accelerate international expansion, and empower The subsidiary’s business pipeline has formed a synergy with the subsidiary’s strong CMC, production, market and hospital network advantages to create version 2.
0 of China Biopharmaceuticals
.
Mao Li said that in order to achieve this strategic plan, the group will establish a high-level international scientific advisory committee, including internationally renowned experts in key fields and experienced former leaders of multinational pharmaceutical companies
.
"We will focus on the varieties with FIC or the first echelon expected to have a peak sales of no less than US$500 million, and focus on differentiated double antibodies, triple antibody platforms, mRNA/DNA technology, radioligand technology, protein modification technology, advanced vaccines and Immunization technology, etc.
; and on this basis, further create original revolutionary innovative technologies
.
"
.
"We will focus on the varieties with FIC or the first echelon expected to have a peak sales of no less than US$500 million, and focus on differentiated double antibodies, triple antibody platforms, mRNA/DNA technology, radioligand technology, protein modification technology, advanced vaccines and Immunization technology, etc.
; and on this basis, further create original revolutionary innovative technologies
.
"
At the same time, X-LAB will cooperate with the Healthy China 2030 plan to explore the path of treatment advancement, such as perioperative and non-surgical radical therapies for tumors and methods to prevent disease
.
Mao Li pointed out that the group will establish an experienced and innovative clinical medical team to grasp the true clinical needs and escort the successful launch of new drugs
.
.
Mao Li pointed out that the group will establish an experienced and innovative clinical medical team to grasp the true clinical needs and escort the successful launch of new drugs
.
On December 4, 2020, China Biopharmaceuticals invested US$515 million in Beijing Kexing Zhongwei Biotechnology Co.
, Ltd.
and obtained 15.
03% of its equity, seeking to transform into a “full industry chain” pharmaceutical company.
This action is highly regarded by the industry.
Concerned
.
Mao Li pointed out that the cooperation with Kexing is more out of strategic investment considerations, which not only lays a very good foundation for Zhongsheng Pharmaceutical to enter the field of anti-infection, but also provides valuable experience for the group's global deployment
.
, Ltd.
and obtained 15.
03% of its equity, seeking to transform into a “full industry chain” pharmaceutical company.
This action is highly regarded by the industry.
Concerned
.
Mao Li pointed out that the cooperation with Kexing is more out of strategic investment considerations, which not only lays a very good foundation for Zhongsheng Pharmaceutical to enter the field of anti-infection, but also provides valuable experience for the group's global deployment
.
Mao Li revealed that the group will form a London-Sweden dual headquarters in Europe, and the London Innovation Center has been established in March this year.
It is looking for advanced technologies and platforms in line with the company's strategy in Europe, which will play an important role in the products entering Europe in the future; Stockholm, Sweden Karolinska Development was established with the help of the Nobel Fund Committee to focus on cooperation with start-up companies with breakthrough technologies
.
The two centers are expected to provide Zhongsheng Pharmaceutical with strategically matched early and mid-term clinical varieties
.
It is looking for advanced technologies and platforms in line with the company's strategy in Europe, which will play an important role in the products entering Europe in the future; Stockholm, Sweden Karolinska Development was established with the help of the Nobel Fund Committee to focus on cooperation with start-up companies with breakthrough technologies
.
The two centers are expected to provide Zhongsheng Pharmaceutical with strategically matched early and mid-term clinical varieties
.
At the same time, Mao Li revealed that Zhongsheng Pharmaceutical is also planning to form a Washington-Houston dual headquarters in North America.
It is optimistic about the Washington-Baltimore Center.
It can use the advantages of the high-speed 270 corridor medical innovation companies and universities to gather innovative technologies and products through cooperation; Houston can further help complete international clinical research by setting up a clinical center
.
It is optimistic about the Washington-Baltimore Center.
It can use the advantages of the high-speed 270 corridor medical innovation companies and universities to gather innovative technologies and products through cooperation; Houston can further help complete international clinical research by setting up a clinical center
.
In June of this year, China Biopharmaceuticals announced that it would establish a global innovative R&D headquarters in Shanghai with its member company Chia Tai Tianqing
.
Mao Li revealed that the group plans to establish a technology innovation R&D platform for the headquarters within 5 years, forming a joint force with the CP Tianqing platform, and becoming the hub for the headquarters to control and coordinate the global R&D system
.
(over)
.
Mao Li revealed that the group plans to establish a technology innovation R&D platform for the headquarters within 5 years, forming a joint force with the CP Tianqing platform, and becoming the hub for the headquarters to control and coordinate the global R&D system
.
(over)
Medical Network, September 2 News China Biopharmaceuticals (HK.
01177) held the 2021 interim results meeting in Beijing on August 31
.
In addition to the various data, the outside concern about Zhongsheng Pharmaceutical also includes the company's countermeasures when the regulation of the pharmaceutical industry enters the deep water zone
.
Mao Li, the Chief Medical Officer (CMO) of Zhongsheng Pharmaceutical, who made his debut at the performance meeting, announced on the same day that he would officially launch the innovation transformation, accelerate the global strategic innovation network layout, and start the X-LAB project
.
01177) held the 2021 interim results meeting in Beijing on August 31
.
In addition to the various data, the outside concern about Zhongsheng Pharmaceutical also includes the company's countermeasures when the regulation of the pharmaceutical industry enters the deep water zone
.
Mao Li, the Chief Medical Officer (CMO) of Zhongsheng Pharmaceutical, who made his debut at the performance meeting, announced on the same day that he would officially launch the innovation transformation, accelerate the global strategic innovation network layout, and start the X-LAB project
.
The industry generally believes that under the new market situation, China's leading pharmaceutical companies will enter an international competitive landscape
.
Internationalization is also a strategic direction that Zhongsheng Pharmaceutical has adhered to for many years
.
"Zhongsheng Pharmaceutical will make every effort to consolidate high-quality development and launch the innovative transformation strategy X-LAB
.
" Mao Li said at the performance meeting that X-LAB's positioning is to strengthen the headquarters’ innovative R&D capabilities, accelerate international expansion, and empower The subsidiary’s business pipeline has formed a synergy with the subsidiary’s strong CMC, production, market and hospital network advantages to create version 2.
0 of China Biopharmaceuticals
.
.
Internationalization is also a strategic direction that Zhongsheng Pharmaceutical has adhered to for many years
.
"Zhongsheng Pharmaceutical will make every effort to consolidate high-quality development and launch the innovative transformation strategy X-LAB
.
" Mao Li said at the performance meeting that X-LAB's positioning is to strengthen the headquarters’ innovative R&D capabilities, accelerate international expansion, and empower The subsidiary’s business pipeline has formed a synergy with the subsidiary’s strong CMC, production, market and hospital network advantages to create version 2.
0 of China Biopharmaceuticals
.
Mao Li said that in order to achieve this strategic plan, the group will establish a high-level international scientific advisory committee, including internationally renowned experts in key fields and experienced former leaders of multinational pharmaceutical companies
.
"We will focus on the varieties with FIC or the first echelon expected to have a peak sales of no less than US$500 million, and focus on differentiated double antibodies, triple antibody platforms, mRNA/DNA technology, radioligand technology, protein modification technology, advanced vaccines and Immunization technology, etc.
; and on this basis, further create original revolutionary innovative technologies
.
"
.
"We will focus on the varieties with FIC or the first echelon expected to have a peak sales of no less than US$500 million, and focus on differentiated double antibodies, triple antibody platforms, mRNA/DNA technology, radioligand technology, protein modification technology, advanced vaccines and Immunization technology, etc.
; and on this basis, further create original revolutionary innovative technologies
.
"
At the same time, X-LAB will cooperate with the Healthy China 2030 plan to explore the path of treatment advancement, such as perioperative and non-surgical radical therapies for tumors and methods to prevent disease
.
Mao Li pointed out that the group will establish an experienced and innovative clinical medical team to grasp the true clinical needs and escort the successful launch of new drugs
.
.
Mao Li pointed out that the group will establish an experienced and innovative clinical medical team to grasp the true clinical needs and escort the successful launch of new drugs
.
On December 4, 2020, China Biopharmaceuticals invested US$515 million in Beijing Kexing Zhongwei Biotechnology Co.
, Ltd.
and obtained 15.
03% of its equity, seeking to transform into a “full industry chain” pharmaceutical company.
This action is highly regarded by the industry.
Concerned
.
Mao Li pointed out that the cooperation with Kexing is more out of strategic investment considerations, which not only lays a very good foundation for Zhongsheng Pharmaceutical to enter the field of anti-infection, but also provides valuable experience for the group's global deployment
.
, Ltd.
and obtained 15.
03% of its equity, seeking to transform into a “full industry chain” pharmaceutical company.
This action is highly regarded by the industry.
Concerned
.
Mao Li pointed out that the cooperation with Kexing is more out of strategic investment considerations, which not only lays a very good foundation for Zhongsheng Pharmaceutical to enter the field of anti-infection, but also provides valuable experience for the group's global deployment
.
Mao Li revealed that the group will form a London-Sweden dual headquarters in Europe, and the London Innovation Center has been established in March this year.
It is looking for advanced technologies and platforms in line with the company's strategy in Europe, which will play an important role in the products entering Europe in the future; Stockholm, Sweden Karolinska Development was established with the help of the Nobel Fund Committee to focus on cooperation with start-up companies with breakthrough technologies
.
The two centers are expected to provide Zhongsheng Pharmaceutical with strategically matched early and mid-term clinical varieties
.
It is looking for advanced technologies and platforms in line with the company's strategy in Europe, which will play an important role in the products entering Europe in the future; Stockholm, Sweden Karolinska Development was established with the help of the Nobel Fund Committee to focus on cooperation with start-up companies with breakthrough technologies
.
The two centers are expected to provide Zhongsheng Pharmaceutical with strategically matched early and mid-term clinical varieties
.
At the same time, Mao Li revealed that Zhongsheng Pharmaceutical is also planning to form a Washington-Houston dual headquarters in North America.
It is optimistic about the Washington-Baltimore Center.
It can use the advantages of the high-speed 270 corridor medical innovation companies and universities to gather innovative technologies and products through cooperation; Houston can further help complete international clinical research by setting up a clinical center
.
It is optimistic about the Washington-Baltimore Center.
It can use the advantages of the high-speed 270 corridor medical innovation companies and universities to gather innovative technologies and products through cooperation; Houston can further help complete international clinical research by setting up a clinical center
.
In June of this year, China Biopharmaceuticals announced that it would establish a global innovative R&D headquarters in Shanghai with its member company Chia Tai Tianqing
.
Mao Li revealed that the group plans to establish a technology innovation R&D platform for the headquarters within 5 years, forming a joint force with the CP Tianqing platform, and becoming the hub for the headquarters to control and coordinate the global R&D system
.
(over)
.
Mao Li revealed that the group plans to establish a technology innovation R&D platform for the headquarters within 5 years, forming a joint force with the CP Tianqing platform, and becoming the hub for the headquarters to control and coordinate the global R&D system
.
(over)
Medical Network, September 2 News China Biopharmaceuticals (HK.
01177) held the 2021 interim results meeting in Beijing on August 31
.
In addition to the various data, the outside concern about Zhongsheng Pharmaceutical also includes the company's countermeasures when the regulation of the pharmaceutical industry enters the deep water zone
.
Mao Li, the Chief Medical Officer (CMO) of Zhongsheng Pharmaceutical, who made his debut at the performance meeting, announced on the same day that he would officially launch the innovation transformation, accelerate the global strategic innovation network layout, and start the X-LAB project
.
01177) held the 2021 interim results meeting in Beijing on August 31
.
In addition to the various data, the outside concern about Zhongsheng Pharmaceutical also includes the company's countermeasures when the regulation of the pharmaceutical industry enters the deep water zone
.
Mao Li, the Chief Medical Officer (CMO) of Zhongsheng Pharmaceutical, who made his debut at the performance meeting, announced on the same day that he would officially launch the innovation transformation, accelerate the global strategic innovation network layout, and start the X-LAB project
.
The industry generally believes that under the new market situation, China's leading pharmaceutical companies will enter an international competitive landscape
.
Internationalization is also a strategic direction that Zhongsheng Pharmaceutical has adhered to for many years
.
"Zhongsheng Pharmaceutical will make every effort to consolidate high-quality development and launch the innovative transformation strategy X-LAB
.
" Mao Li said at the performance meeting that X-LAB's positioning is to strengthen the headquarters’ innovative R&D capabilities, accelerate international expansion, and empower The subsidiary’s business pipeline has formed a synergy with the subsidiary’s strong CMC, production, market and hospital network advantages to create version 2.
0 of China Biopharmaceuticals
.
Hospital hospital hospital.
Internationalization is also a strategic direction that Zhongsheng Pharmaceutical has adhered to for many years
.
"Zhongsheng Pharmaceutical will make every effort to consolidate high-quality development and launch the innovative transformation strategy X-LAB
.
" Mao Li said at the performance meeting that X-LAB's positioning is to strengthen the headquarters’ innovative R&D capabilities, accelerate international expansion, and empower The subsidiary’s business pipeline has formed a synergy with the subsidiary’s strong CMC, production, market and hospital network advantages to create version 2.
0 of China Biopharmaceuticals
.
Mao Li said that in order to achieve this strategic plan, the group will establish a high-level international scientific advisory committee, including internationally renowned experts in key fields and experienced former leaders of multinational pharmaceutical companies
.
"We will focus on the varieties with FIC or the first echelon expected to have a peak sales of no less than US$500 million, and focus on differentiated double antibodies, triple antibody platforms, mRNA/DNA technology, radioligand technology, protein modification technology, advanced vaccines and Immunization technology, etc.
; and on this basis, further create original revolutionary innovative technologies
.
"
.
"We will focus on the varieties with FIC or the first echelon expected to have a peak sales of no less than US$500 million, and focus on differentiated double antibodies, triple antibody platforms, mRNA/DNA technology, radioligand technology, protein modification technology, advanced vaccines and Immunization technology, etc.
; and on this basis, further create original revolutionary innovative technologies
.
"
At the same time, X-LAB will cooperate with the Healthy China 2030 plan to explore the path of treatment advancement, such as perioperative and non-surgical radical therapies for tumors and methods to prevent disease
.
Mao Li pointed out that the group will establish an experienced and innovative clinical medical team to grasp the true clinical needs and escort the successful launch of new drugs
.
Health Health health diseases disease disease.
Mao Li pointed out that the group will establish an experienced and innovative clinical medical team to grasp the true clinical needs and escort the successful launch of new drugs
.
On December 4, 2020, China Biopharmaceuticals invested US$515 million in Beijing Kexing Zhongwei Biotechnology Co.
, Ltd.
and obtained 15.
03% of its equity, seeking to transform into a “full industry chain” pharmaceutical company.
This action is highly regarded by the industry.
Concerned
.
Mao Li pointed out that the cooperation with Kexing is more out of strategic investment considerations, which not only lays a very good foundation for Zhongsheng Pharmaceutical to enter the field of anti-infection, but also provides valuable experience for the group's global deployment
.
, Ltd.
and obtained 15.
03% of its equity, seeking to transform into a “full industry chain” pharmaceutical company.
This action is highly regarded by the industry.
Concerned
.
Mao Li pointed out that the cooperation with Kexing is more out of strategic investment considerations, which not only lays a very good foundation for Zhongsheng Pharmaceutical to enter the field of anti-infection, but also provides valuable experience for the group's global deployment
.
Mao Li revealed that the group will form a London-Sweden dual headquarters in Europe, and the London Innovation Center has been established in March this year.
It is looking for advanced technologies and platforms in line with the company's strategy in Europe, which will play an important role in the products entering Europe in the future; Stockholm, Sweden Karolinska Development was established with the help of the Nobel Fund Committee to focus on cooperation with start-up companies with breakthrough technologies
.
The two centers are expected to provide Zhongsheng Pharmaceutical with strategically matched early and mid-term clinical varieties
.
It is looking for advanced technologies and platforms in line with the company's strategy in Europe, which will play an important role in the products entering Europe in the future; Stockholm, Sweden Karolinska Development was established with the help of the Nobel Fund Committee to focus on cooperation with start-up companies with breakthrough technologies
.
The two centers are expected to provide Zhongsheng Pharmaceutical with strategically matched early and mid-term clinical varieties
.
At the same time, Mao Li revealed that Zhongsheng Pharmaceutical is also planning to form a Washington-Houston dual headquarters in North America.
It is optimistic about the Washington-Baltimore Center.
It can use the advantages of the high-speed 270 corridor medical innovation companies and universities to gather innovative technologies and products through cooperation; Houston can further help complete international clinical research by setting up a clinical center
.
Medicine Medicine MedicineIt is optimistic about the Washington-Baltimore Center.
It can use the advantages of the high-speed 270 corridor medical innovation companies and universities to gather innovative technologies and products through cooperation; Houston can further help complete international clinical research by setting up a clinical center
.
In June of this year, China Biopharmaceuticals announced that it would establish a global innovative R&D headquarters in Shanghai with its member company Chia Tai Tianqing
.
Mao Li revealed that the group plans to establish a technology innovation R&D platform for the headquarters within 5 years, forming a joint force with the CP Tianqing platform, and becoming the hub for the headquarters to control and coordinate the global R&D system
.
(over)
Enterprise business enterprise .
Mao Li revealed that the group plans to establish a technology innovation R&D platform for the headquarters within 5 years, forming a joint force with the CP Tianqing platform, and becoming the hub for the headquarters to control and coordinate the global R&D system
.
(over)
